Daiichi Sankyo: FDA Grants Priority Review For ENHERTU

The U.S. FDA accepted and granted Priority Review to Daiichi Sankyo and AstraZeneca's supplemental BLA for ENHERTU for adult HER2‑positive breast cancer. Priority Review shortens the regulatory timeline (typically to ~6 months), de‑risking the approval path and improving the drug's commercial outlook; this is likely to move the companies' shares in the low single‑digit percentage range and increase near‑term valuation optionality.

Analysis

The U.S. FDA accepted and granted Priority Review to Daiichi Sankyo and AstraZeneca's supplemental BLA for ENHERTU for adult HER2‑positive breast cancer. Priority Review shortens the regulatory timeline (typically to ~6 months), de‑risking the approval path and improving the drug's commercial outlook; this is likely to move the companies' shares in the low single‑digit percentage range and increase near‑term valuation optionality.